Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 14/20 | 0.78 |
| ▸ | BCR | P11274 | 12/20 | 0.78 |
| ▸ | SRC | P12931 | 2/20 | 0.60 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.57 |
| ▸ | LDLR | P01130 | 1/20 | 0.56 |
| ▸ | KIT | P10721 | 1/20 | 0.56 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.56 |
| ▸ | TEK | Q02763 | 1/20 | 0.56 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.55 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29515084 | 1.00 | ABL1 (0.78) | ABL1BCRSRCNR2E1LDLR | |
| SCHEMBL29514885 | 0.88 | ABL1 (0.78) | ABL1BCRSRCNR2E1LDLR | |
| SCHEMBL14953321 | 0.88 | ABL1 (0.78) | ABL1BCRSRCNR2E1LDLR | |
| SCHEMBL3428132 | 0.88 | ABL1 (1.00) | ABL1BCRSRCNR2E1LDLR | |
| SCHEMBL29515144 | 0.88 | ABL1 (1.00) | ABL1BCRSRCNR2E1LDLR | |
| SCHEMBL29514917 | 0.87 | ABL1 (0.79) | ABL1BCRSRCNR2E1LDLR | |
| SCHEMBL3435403 | 0.87 | ABL1 (0.79) | ABL1BCRSRCNR2E1LDLR | |
| SCHEMBL14953064 | 0.86 | ABL1 (1.00) | ABL1BCRSRCNR2E1LDLR | |
| SCHEMBL27914922 | 0.86 | ABL1 (0.77) | ABL1BCRSRCNR2E1LDLR | |
| SCHEMBL24626536 | 0.86 | ABL1 (0.84) | ABL1BCRSRCNR2E1LDLR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250235426-A1 | Pharmaceutical Combination and Use Thereof | ASCENTAGE PHARMA GROUP CORP LIMITED (CN) | 2025-07-24 | — | — | US | claimed |
| US-20220142975-A1 | Pharmaceutical Combination and Use Thereof | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-05-12 | — | — | US | claimed |
| CN-112237579-A | Pharmaceutical composition and use thereof | 苏州亚盛药业有限公司 | 2021-01-19 | — | — | CN | claimed |
| US-20130196985-A1 | HETEROCYCLIC ALKYNYL BENZENE COMPOUNDS AND MEDICAL COMPOSITIONS AND USES THEREOF | Guangzzhou Institute of Biomedicine and Health, Chineses Academy of Sciences (CN) | 2013-08-01 | — | — | US | claimed |
| EP-2594567-A1 | HETEROCYCLIC ALKYNYL BENZENE COMPOUNDS AND MEDICAL COMPOSITIONS AND USES THEREOF | Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences (CN) | 2013-05-22 | — | — | EP | claimed |
| US-20250235426-A1 | Pharmaceutical Combination and Use Thereof | ASCENTAGE PHARMA GROUP CORP LIMITED (CN) | 2025-07-24 | — | — | US | disclosed |
| US-12233047-B2 | Pharmaceutical combination and use thereof | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2025-02-25 | — | — | US | disclosed |
| US-20220142975-A1 | Pharmaceutical Combination and Use Thereof | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-05-12 | — | — | US | disclosed |
| CN-112237579-B | Pharmaceutical composition and use thereof | 苏州亚盛药业有限公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-112237579-A | Pharmaceutical composition and use thereof | 苏州亚盛药业有限公司 | 2021-01-19 | — | — | CN | disclosed |
| EP-3741751-A1 | HETEROCYCLIC ALKYNYL BENZENE COMPOUNDS AND MEDICAL COMPOSITIONS AND USES THEREOF | Guangzhou Healthquest Pharma Co., Ltd. (CN) | 2020-11-25 | — | — | EP | disclosed |
| EP-3741751-A1 | HETEROCYCLIC ALKYNYL BENZENE COMPOUNDS AND MEDICAL COMPOSITIONS AND USES THEREOF | Guangzhou Healthquest Pharma Co., Ltd. (CN) | 2020-11-25 | — | — | EP | disclosed |
| US-8846671-B2 | Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof | GUANGZHOU INSTITUTE OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2014-09-30 | — | — | US | disclosed |
| US-20130196985-A1 | HETEROCYCLIC ALKYNYL BENZENE COMPOUNDS AND MEDICAL COMPOSITIONS AND USES THEREOF | Guangzzhou Institute of Biomedicine and Health, Chineses Academy of Sciences (CN) | 2013-08-01 | — | — | US | disclosed |
| US-20130196985-A1 | HETEROCYCLIC ALKYNYL BENZENE COMPOUNDS AND MEDICAL COMPOSITIONS AND USES THEREOF | Guangzzhou Institute of Biomedicine and Health, Chineses Academy of Sciences (CN) | 2013-08-01 | — | — | US | disclosed |
| CN-101885722-B | Heterocycle alkyne and benzene compound, medicinal composition and application thereof | GUANGZHOU INST BIOMED & HEALTH | 2013-07-24 | — | — | CN | disclosed |
| EP-2594567-A1 | HETEROCYCLIC ALKYNYL BENZENE COMPOUNDS AND MEDICAL COMPOSITIONS AND USES THEREOF | Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences (CN) | 2013-05-22 | — | — | EP | disclosed |
| EP-2594567-A1 | HETEROCYCLIC ALKYNYL BENZENE COMPOUNDS AND MEDICAL COMPOSITIONS AND USES THEREOF | Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences (CN) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012000304-A1 | HETEROCYCLIC ALKYNYL BENZENE COMPOUNDS AND MEDICAL COMPOSITIONS AND USES THEREOF | 中国科学院广州生物医药与健康研究院 (CN) | 2012-01-05 | — | — | WO | disclosed |
| CN-101885722-A | Heterocycle alkyne and benzene compound, medicinal composition and application thereof | GUANGZHOU INST BIOMED & HEALTH | 2010-11-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196985-A1 | HETEROCYCLIC ALKYNYL BENZENE COMPOUNDS AND MEDICAL COMPOSITIONS AND USES THEREOF | ABCB1, VHL, ABCC1 | ABL1 23/4885BCR 16/4885SRC 276/4885 |
| US-12233047-B2 | Pharmaceutical combination and use thereof | SLC5A6, SLC10A1, SLC26A4 | ABL1 653/4885BCR 3365/4885SRC 567/4885 |
| US-20250235426-A1 | Pharmaceutical Combination and Use Thereof | SLC5A6, SLC10A1, SLC26A4 | ABL1 640/4885BCR 3281/4885SRC 565/4885 |
| US-20220142975-A1 | Pharmaceutical Combination and Use Thereof | SLC5A6, SLC10A1, SLC26A4 | ABL1 653/4885BCR 3365/4885SRC 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.